Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jul 3;17(1):252.
doi: 10.1186/s13098-025-01762-0.

Emerging phenotype: Maturity-onset diabetes of the young type 5 (MODY-5) - mechanisms, clinical spectrum, and unmet needs

Fahrul Nurkolis  1   2   3 , Rony Abdi Syahputra  4 , Andika Priamas Nugrahanto  5 , Nurpudji Astuti Taslim  6 , Arifa Mustika  7 , Raymond Rubianto Tjandrawinata  8 , Dante Saksono Harbuwono  9   10 , Sidartawan Soegondo  9   11
Affiliations
Review

Emerging phenotype: Maturity-onset diabetes of the young type 5 (MODY-5) - mechanisms, clinical spectrum, and unmet needs

Fahrul Nurkolis et al. Diabetol Metab Syndr. .

Abstract

Type 5 Diabetes or MODY-5 has recently emerged as a rare yet distinct phenotype among pediatric diabetes disorders, characterized predominantly by mutations in critical genes such as HNF1B and PPARG. Unlike more common diabetes types, this atypical form demonstrates extensive multisystem involvement, presenting clinically through diverse manifestations including renal cysts, pancreatic hypoplasia, growth disturbances, and neurological complications. Genetic analyses underscore its significant heterogeneity, illustrating a complex interplay among genetic mutations, epigenetic modifications, and environmental triggers that collectively shape its distinct pathogenesis. Molecular disruptions prominently include alterations in NF-κB signaling pathways, increased oxidative stress, mitochondrial dysfunction, and heightened profibrotic TGF-β activity, leading to early and severe multisystem complications. Despite these insights, clinical misclassification remains frequent, largely because diagnostic tools continue to prioritize conventional parameters such as HbA1c and fasting glucose rather than molecular diagnostics. Moreover, the absence of validated biomarkers specific to Type 5 Diabetes further impedes timely and precise diagnosis, underscoring critical gaps in current clinical practice. Addressing these diagnostic and therapeutic gaps necessitates expanded genetic screening, enhanced clinician education, and the establishment of subtype-specific clinical guidelines. This review proposes a structured framework to drive future diagnostic and therapeutic advancements, ultimately facilitating personalized management and improved outcomes for affected pediatric populations.

Keywords: Clinical management; Epigenetics; HNF1B; Molecular diagnostics; Monogenic diabetes; PPARG; Pediatric diabetes; Precision medicine; Type 5 diabetes.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics and consent to participate declarations: Not applicable. Consent to publish: Not applicable. Informed consent: Not applicable. AI statements: During the revision of this work the author(s) used ChatGPT in order to correct the language and paraphrase the necessary sections. After using this tool/service, the author(s) reviewed and edited the content as necessary and took full responsibility for the content of the published article. Authors are ultimately responsible and accountable for the contents of the work. We acknowledge the use of AI assistance, specifically ChatGPT, for language refinement and improving the clarity and conciseness of the manuscript. No AI tools were used for data analysis, interpretation, or generating scientific content. All scientific concepts, results, and conclusions were developed and verified by the authors. Clinical trials: Not applicable. Institutional review board statement: Not applicable. Competing interests: The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Molecular Pathways Implicated in Type 5 Diabetes Progression. A detailed depiction of disrupted molecular pathways, including NF-κB activation, oxidative stress, mitochondrial dysfunction, and TGF-β-mediated fibrosis contributing to the early-onset systemic complications. Created with BioRender.com Premium License by Fahrul Nurkolis (https://app.biorender.com, accessed on 05 March 2025)
Fig. 2
Fig. 2
Proposed Mechanistic Model of Type 5 Diabetes Development. A schematic model illustrating the interplay between genetic mutations (e.g., HNF1B, PPARG), epigenetic modifications (DNA methylation, histone changes), and environmental triggers (e.g., diet, infections) leading to multisystemic manifestations in Type 5 Diabetes among children. Created with BioRender.com Premium License by Fahrul Nurkolis (https://app.biorender.com, accessed on 05 March 2025)
Fig. 3
Fig. 3
Comparative Pathophysiology of Pediatric Diabetes Subtypes. A comparative diagram contrasting the major pathophysiological mechanisms among Type 1, Type 2, and Type 5 Diabetes (MODY-5), highlighting autoimmune, insulin resistance, and genetic-multisystem involvement, respectively. infections) leading to multisystemic manifestations in Type 5 Diabetes among children. Created with BioRender.com Premium License by Fahrul Nurkolis (https://app.biorender.com, accessed on 05 March 2025)
Fig. 4
Fig. 4
Clinical Spectrum of Type 5 Diabetes (MODY-5) by Age of Onset. A visual summary displaying the variable age at onset of Type 5 Diabetes and its associated systemic complications such as renal anomalies, pancreatic dysplasia, and neurological deficits. infections) leading to multisystemic manifestations in Type 5 Diabetes among children. Created with BioRender.com Premium License by Fahrul Nurkolis (https://app.biorender.com, accessed on 05 March 2025)
Fig. 5
Fig. 5
Diagnostic Challenges and Misclassification Pathways. Flowchart outlining the typical diagnostic misclassification pathway of pediatric Type 5 Diabetes, emphasizing where conventional methods fail and where molecular diagnostics could intervene. Created with BioRender.com Premium License by Fahrul Nurkolis (https://app.biorender.com, accessed on 05 March 2025)
Fig. 6
Fig. 6
Future Directions for Research and Clinical Management. Proposed roadmap for advancing Type 5 Diabetes care, including biomarker discovery, genetic screening integration, multi-omic research, and individualized treatment frameworks. Created with BioRender.com Premium License by Fahrul Nurkolis (https://app.biorender.com, accessed on 05 March 2025)
See this image and copyright information in PMC

References

    1. Goyal S, Vanita V. The rise of Type 2 diabetes in children and adolescents: An emerging pandemic. Diabetes Metab Res Rev [Internet]. 2025;41:e70029. Available from: 10.1002/dmrr.70029 - PubMed
    1. Shah AS, Zeitler PS, Wong J, Pena AS, Wicklow B, Arslanian S et al. ISPAD Clinical Practice Consensus Guidelines 2022: Type 2 diabetes in children and adolescents. Pediatr Diabetes [Internet]. 2022;23:872–902. Available from: 10.1111/pedi.13409 - PubMed
    1. Haider A, Symczyk O, Hassan A, Khan MA, Madahar I, Holland D. Maturity-onset diabetes of young type 5: Diabetes with extrapancreatic features. Case Rep Endocrinol [Internet]. 2021;2021:8243471. Available from: 10.1155/2021/8243471 - PMC - PubMed
    1. Amaral S, Palha A, Bogalho P, Silva-Nunes J. Maturity-onset diabetes of the young secondary to HNF1B variants (HNF1B-MODY): a series of 10 patients from a single diabetes center. Diabetol Metab Syndr [Internet]. 2023;15:21. Available from: 10.1186/s13098-022-00964-0 - PMC - PubMed
    1. Bauer W, Gyenesei A, Krętowski A. The multifactorial progression from the islet autoimmunity to type 1 Diabetes in children. Int J Mol Sci [Internet]. 2021;22:7493. Available from: 10.3390/ijms22147493 - PMC - PubMed

LinkOut - more resources